Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$30,000.00
May 2, 2022
For-profit organization
YOUTH Project: Manufacturing and Regulatory Affairs
989182
This project will serve to advance Inversago’s CB1 inverse agonist development programs to provide new therapies aimed at improving the lives of patients affected by metabolic and fibrotic conditions.
$249,500.00
Sep 13, 2021
For-profit organization
Development of Novel CB1 Blockers
978964
The ultimate goal of the project is to develop new generation CB1 receptor blockers for clinical advancement applying key learnings from its CB1 receptor antagonist program.
$300,000.00
Jul 15, 2019
For-profit organization
Prader-Willi syndrome - therapy development.
934003
Chemical manufacturing process scale-up and optimization of API as well as formulation development and in vivo confirmation.